CD8A and neoplasm: Some of these include the licensing of CD8 + T cells (Schietinger et al., 2010), cytotoxic killing of tumor cells expressing MHC-II (Lundin et al., 2003; Quezada et al., 2010), macrophage (Corthay et al., 2005) and natural killer (NK) cell activation (Corthay et al., 2005) and cytokine-mediated effects on the tumor vascular system (Qin and Blankenstein, 2000).